Pfizer Inc. news

   Watch this stock
Showing stories 11 - 20 of about 167   

Articles published

PFE 31.83 0.00 (0.00%)
price chart
Company Watch: Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE:PFE), which has been linked to a long list of other companies since giving up its pursuit of AstraZeneca (AZN), doesn't need to do a big deal to succeed, according to CEO Ian Read, reported Financial Times.
Pfizer Will Do Fine Without AstraZeneca
Their opinions in no way represent those of Barrons.com or Dow Jones & Company, Inc. Some of the reports' issuers have provided, or hope to provide, investment-banking or other services to the companies being analyzed.
Does Pfizer Inc. Stock Offer a Market-Crushing Opportunity in 2015?
The first step was the IPO of Pfizer's animal health business that gave rise to Zoetis (NYSE: ZTS ) in June 2013. That move cleared the way for the next step, namely reorganizing the company into three operational units: global innovative ...
Pfizer to Cut Prevenar 13 Price Again
Pfizer Inc. said Monday it would cut the price of its pneumococcal vaccine for the third time in three years as the pharmaceutical industry faces criticism over skyrocketing vaccine prices in developing markets.
Pfizer Inc. (NYSE:PFE) Announces New Commitments  Inside Trade
Pfizer Inc. (PFE) Will Further Reduce Prevenar 13 Price In The World's ...  Bidness ETC
Pfizer Inc. (PFE) Closes 0.38% Down on the Day for January 29
Dow Jones component Pfizer Inc. ($PFE) saw its stock move -0.38% to $31.83, representing a per-share move of $0.12, on volume of 29.04 million shares for Thursday.
Pfizer Inc. (PFE), Alliance HealthCare Services, Inc. (AIQ), Skilled ...
Anders Hallberg and Carl Bennet's HealthInvest Partners AB revealed its top picks for the fourth quarter of 2014. According to the 13F Form filed with the U.S.
Pfizer Forecast Falls Short on Patent Expiration, Currency
(Bloomberg) -- Pfizer Inc., the biggest U.S. drugmaker, forecast a decline in sales this year as patent expirations and a stronger dollar weigh on revenue.
Pfizer net down on lower sales, higher research, legal costs  Barre Montpelier Times Argus
Pfizer Inc. (NYSE:PFE) Says Foreign Exchange Will Hurt 2015 Sales ...
Pfizer Inc. (NYSE:PFE) [Trend Analysis] reported that a strong U.S. dollar as well as current drug-patent losses contributed to a 52 percent decrease in net income in the Q4 and would depress results this year.
Pfizer's Hunt Said to Have Included Rebuffed Teva Approach
(Bloomberg) -- In pursuit of growth, Pfizer Inc. is casting a wide net that included an approach to Teva Pharmaceutical Industries Ltd.
Stock Insights on Pfizer Inc (NYSE:PFE)
Pfizer Inc (NYSE:PFE) (TREND ANALYSIS) shares were traded near the 52-week high of $33.5. The stock closed last trading session at $32.45, with a volume of 25,975,881 shares against an average volume for the last 30 days of 26,098,314.